Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
about
Preclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsIncidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysisPrediction of cancer drugs by chemical-chemical interactionsShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.Targeted therapies in renal cell cancer: recent developments in imagingFunction of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancerPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisDynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibAntiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLCCorrelation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancerTargeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondNew molecular targeted therapies for advanced non-small-cell lung cancer.Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanibVascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS MutationsAdding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerSorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer.A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewAntiangiogenic therapy for cancer: an updateHIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.Novel targets in non-small cell lung cancer: ROS1 and RET fusionsMorphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case reportComprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trialSecond-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.Role of epidermal growth factor receptor in lung cancer and targeted therapies.Targeted therapy: an evolving world of lung cancer.
P2860
Q26863474-98F80CF9-A6F7-4599-80F0-469A38B8723EQ27003304-85A346E2-69CF-4D39-8B23-474FC8C7AAC7Q28539449-E25C2CA5-8237-41A9-8513-4AAB7B89F03FQ30240170-4C71242E-3146-4E13-818F-B9815FEC7498Q33633424-D981DB40-3476-48AE-89A4-7E4961B46E34Q33988445-A4AB48A7-EFFF-4E26-BFA5-93A3133C201FQ33990928-6D325672-165C-47F2-A8D3-ABE7D1409572Q34088696-15DEC773-FD2E-4074-A5D3-DB11BEBC8F0FQ34094975-7AA8B8D3-A6E7-40AC-A618-587AB8254F31Q34272887-FADE93E2-0316-410A-A3D7-78B9DD9CD722Q34298000-EC235086-70A3-4184-95F4-47C2131876C5Q34300117-06ECE4FB-BC4E-4829-B44E-085874658911Q34625305-DA4C2525-CD43-4EB1-8D3A-3B19F6FDB785Q34854658-0F759D04-7397-4E79-94F5-D44D90B1FECEQ34983846-F40B8F0F-FCAE-45D3-B3B2-F9727CA1C215Q35050210-F17F06DF-062B-491C-AEDD-093973FD9772Q35068706-7DABAEDE-1C70-4927-B094-95264616299BQ35584072-04CA112D-665A-4D35-9F4C-87B745757783Q35584074-32D39895-6415-4B07-9FD3-7431B6060FF1Q35660763-12EE831F-A7A2-4AAA-A60B-3DF7B99E8F6AQ35667806-CBC9D801-A28A-4551-96C4-BA4419EE56FBQ35883400-5E4BF7AF-7336-447B-B0B7-381A3644BCDAQ35939630-E3E679E0-C854-4262-92A4-8E2F97D41607Q35971891-6C1C8108-5F8B-4EC6-A549-A6B28573A1E7Q36161541-52D547E0-7385-41D8-9F6F-44963097CD0CQ36185594-DC679438-207F-4BBC-9F31-E5C213FF2785Q36241287-2C33D9FF-B7AB-4F33-97DA-00F7F1804CB3Q36270034-99EBFC48-C640-4BAA-BCD1-842CABA66F02Q36270115-10A83851-BD79-4C9F-8BA7-8C1E8EC0C55CQ36563542-A159EDE5-3FD5-4557-8AB8-E0EAB079A604Q36822204-EAB51B0D-19D0-4D59-A467-B9B8BB660ADAQ36920386-C4E02778-FE90-4F5E-905D-38535B0660F2Q37038500-C7C87AF7-8F80-4DC1-AACE-E9FC63110B72Q37051227-36895A56-BBBA-43C1-9372-D56D3BEC4400Q37188509-413F22B1-8CE0-49E8-A6C2-AA050297E685Q37403333-B5441CEF-606E-428B-9AD1-FD355054791CQ37526488-0C6A92C6-A8BC-4B3B-997B-E165F550A72EQ37670497-14C9E670-B6D5-4C3E-9A4E-8B6AA453DDC7Q37679981-759FA258-C124-4A3E-A2CF-10DDDF2941C0Q37781113-19DF4866-2542-474E-990D-4A8372E934AE
P2860
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@en
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@nl
type
label
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@en
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@nl
prefLabel
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@en
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@nl
P2093
P356
P1476
Phase II, multicenter, uncontr ...... ed non-small-cell lung cancer.
@en
P2093
David J Stewart
Frank Cihon
James O'Leary
Lisa Cupit
Martin Reck
Ulrich Gatzemeier
P304
P356
10.1200/JCO.2009.22.0541
P407
P577
2009-08-03T00:00:00Z